ArticleCancer science2017

ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.

Aya Kikuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.